Multiple Myeloma

9 protocols meet the specified criteria.

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • BB2121-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

  • CA057-008

    A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  • CL04-ORY-1001

    An escalation/expansion, Open label, Multicenter study of iadademstat and gilteribinib in patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+): The FRIDA Study

  • EA9171

    Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

  • EAA173

    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

  • NCBP6637-01

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients